Ivabradine + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Postural Orthostatic Tachycardia Syndrome
Conditions
Postural Orthostatic Tachycardia Syndrome
Trial Timeline
Feb 6, 2018 → May 8, 2020
NCT ID
NCT03182725About Ivabradine + Placebo
Ivabradine + Placebo is a phase 3 stage product being developed by Amgen for Postural Orthostatic Tachycardia Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT03182725. Target conditions include Postural Orthostatic Tachycardia Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03168529 | Approved | Terminated |
| NCT03387605 | Approved | UNKNOWN |
| NCT03182725 | Phase 3 | Completed |
Competing Products
6 competing products in Postural Orthostatic Tachycardia Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| REGN7544 + Placebo | Regeneron Pharmaceuticals | Phase 2 | 51 |
| IgPro20 + Placebo | CSL | Phase 3 | 76 |
| Efgartigimod | Argenx | Phase 2 | 49 |
| Efgartigimod + Placebo | Argenx | Phase 2 | 49 |
| Northera (Droxidopa) + Placebo + Northera (Droxidopa) + Placebo | Lundbeck | Phase 2 | 49 |
| IVIG + Albumin | Grifols | Phase 1/2 | 38 |